Background: Measles outbreaks continue to occur in the United States and are mostly due to infections in returning travelers.
I
n 2000, endemic measles was eliminated in the United States (1) . Nevertheless, measles outbreaks persist because of imported cases (2) . More than half of such measles importations occur in returning unvaccinated U.S. travelers who acquire infection with measles while abroad; these individuals may infect others after their return to the United States (3) .
Since 1989, the Advisory Committee on Immunization Practices (ACIP) has recommended 2 documented doses of measles, mumps, rubella (MMR) vaccine for all adult international travelers without evidence of previous measles immunity (4, 5) . The risk for measles is greatly increased outside the United States (6, 7) , and air travel has been associated with measles transmission (8) . When evaluating patients before international travel, some health care providers may not be aware that measles is a travel-associated illness, despite ACIP recommendations.
A single imported measles case can lead to many secondary and tertiary cases, so imported measles cases often have a wide-reaching effect in the United States (2) . Measles spreads via aerosolized droplets and is highly infectious; 90% of exposed, unvaccinated people will become ill with measles after entering a room that had housed an infected person for as long as 2 hours beforehand (9) . The risks for measles transmission are magnified in communities with a higher prevalence of unvaccinated adults and children (10) ; in the so-called Disneyland outbreak of measles in 2015, for example, an infected visitor to Disneyland led to 147 reported cases in 7 states (11) . Similarly, just 2 imported measles cases from travelers returning from the Philippines in 2014 led to an outbreak of 383 cases in Ohio in a primarily unvaccinated Amish community (12, 13) .
In this multisite observational study, our goals were to describe how clinicians who are experienced in providing pretravel medical advice assess for measles immunity at pretravel health consultations and to examine reasons for nonvaccination among patients who are eligible for the MMR vaccine.
METHODS

Study Setting
Global TravEpiNet (GTEN) is a consortium of clinical sites throughout the United States that provide pretravel health advice and vaccination (14) . Fourteen sites are academic centers affiliated with university hospitals or medical schools; the other 10 sites are primary care practices, pharmacies, and public health clinics. Each GTEN site prospectively and systematically collects data on every pretravel health consultation. The 24 sites that contributed data to this analysis are in 4 census regions of the United States: Northeast (8 sites), Midwest (2 sites), South (8 sites), and West (6 sites) (15) .
An institutional review board at all 24 participating sites either approved the study or considered it exempt from review.
Study Population and Eligibility Criteria
Travelers were included if they were aged 18 years or older when they visited a GTEN clinical site for pretravel health consultation between 1 January 2009 and 31 December 2014. Travelers born before 1957 were excluded because life long natural measles immunity is assumed in this age group; thus, ACIP does not recommend MMR vaccination for this group (4, 5) .
Data Collection, Assessment of Measles Immunity and MMR Eligibility, and Clinical Management of the MMR-Eligible
During the pretravel consultation, travelers and providers used an online structured questionnaire, as previously described (14, 16) . Travelers entered information on their age, medical conditions, and travel itinerary (for example, destination, reason for travel, and duration of travel) into the structured questionnaire. Providers confirmed the information entered by the traveler and then entered additional data about immunization history, health advice provided, vaccines administered (including MMR), and medications prescribed during the pretravel consultation.
Providers assessed travelers' measles immunity status during the pretravel health consultation in accordance with their routine clinical practice. As such, selfreported immunization or measles illness history may have been accepted. The structured questionnaire required providers to characterize their assessment of measles immunity in 1 of 4 ways: 1) a history of 2 MMR vaccinations, 2) a positive result on measles serologic testing, 3) a previous measles illness, or 4) "immune per provider judgment" (that is, the provider considered the traveler immune but did not indicate a specific reason).
Regardless of the time until departure, the structured questionnaire required providers to consider MMR vaccination for all travelers not considered immune for one of the reasons listed above and who had no medical contraindication to MMR vaccination (for example, pregnancy or immunosuppression), as per ACIP guidelines (4, 5) . In this analysis, we term these travelers "MMR-eligible." If providers did not vaccinate an MMR-eligible traveler, they were required to select 1 of the following 5 explanations: 1) traveler refusal, 2) vaccination not indicated for this patient/itinerary, 3) insufficient time for vaccination before departure, 4) vaccine unavailable at the clinic, or 5) referral to another provider for vaccination. Before 2012, providers did not record a specific reason for traveler refusal of a recommended MMR vaccine. Beginning in 2012, providers were required to select only 1 of the following 3 reasons for why travelers refused vaccination: 1) Traveler is concerned about vaccine safety, 2) traveler is concerned about vaccine cost, or 3) traveler is not concerned about the vaccine-preventable illness.
Statistical Analyses
We categorized adult travelers into 2 cohorts depending on their birth year (1957 to 1989 and 1990 or later) because the recommendation to routinely vaccinate all children aged 1 year or older with 2 doses of MMR vaccine began in 1989 (4, 5) .
We grouped destination countries into 6 geographic regions, as defined by the World Health Organization in 2012: the Americas, Africa, Eastern Mediterranean, Europe, Southeast Asia, and Western Pacific (17) . Reasons for travel included business, humanitarian service work, leisure, research/education, visiting friends and relatives (VFR), and other (18) . We defined VFR travelers according to the CDC definition: travelers to a low-or low-middle-income country of their or their parents' birth who stated the reason for travel was "traveling to region of origin of self or family to visit friends or relatives" or who noted that they would stay with relatives during the itinerary (19) . We dichotomized travel duration into less than 14 days and 14 days or longer (14 days being the median duration). We categorized the location of GTEN clinic sites into the 4 U.S. census regions (Northeast, Midwest, South, West). We dichotomized the type of clinic into academic centers (14 sites that were affiliated with university hospitals or medical schools) and nonacademic centers (10 sites that were primary care practices, pharmacies, and public health clinics). We grouped reasons that were provided for not vaccinating the MMReligible into 3 categories: traveler refusal (traveler declined because of lack of concern about measles or concerns about vaccine safety or cost), provider decision (provider considered that the vaccine was not indicated or provider reported that there was insufficient time to vaccinate before travel), and health systems barriers (the traveler was referred to another provider for vaccination or the vaccine was unavailable at the travel clinic).
Analyses were conducted by using SAS software, version 9.2 (SAS Institute). We obtained summary statistics (proportions, means, medians, and SDs) for the demographic and travel-related characteristics (overall and within subgroups of travelers with measles immunity, medical contraindication to vaccination, vaccine eligibility, and nonvaccination among the MMReligible) in the 4 U.S. census regions.
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RESULTS
Providers assessed 54 100 adult travelers at 24 GTEN sites (Figure) . We excluded 13 290 travelers because they were born before 1957 and therefore were presumed to be immune to measles infection. The distribution of sites and travelers from the U.S. census regions is described in Appendix Table 1 (available at Annals.org).
Of the 40 810 study participants, 22 987 (56%) were female ( Table 1) . The median age of travelers was 33 years (interquartile range, 26 to 44 years); 35 035 (86%) were born between 1957 and 1989. Africa was the most common destination region, with 14 471 (35%) travelers, followed by 11 562 (28%) travelers to the Americas. Of all travelers, 20 507 (50%) were plan- MMR Vaccination in U.S. Adult Travelers ORIGINAL RESEARCH ning travel for leisure; 3208 (8%) were VFR travelers. The median duration of travel was 14 days (interquartile range, 10 to 24 days). Providers deemed 34 092 travelers (84%) to be immune to measles on the basis of their clinical assessment. Of these, providers considered 24 884 to be immune because of a history of receiving 2 MMR vaccinations, 3479 because of a positive result on measles serologic testing, and 1024 because of a history of measles illness; the remainder were considered immune per provider judgment (5985 [18%]) (Figure) . Among the 6718 nonimmune travelers, 106 had a medical contraindication to MMR vaccination. A total of 6612 (16%) adult travelers were therefore eligible for MMR vaccination at the pretravel consultation.
Providers were required to consider MMR vaccination for all international travelers. Of the 6612 MMReligible travelers, 3477 (53%) were not vaccinated at the pretravel encounter (Figure) . Providers were required to provide a rationale when MMR vaccine was not administered to travelers who were MMR-eligible (Figure) . Of the 3477 MMReligible travelers who were not vaccinated, 1689 (48%) did not receive the vaccine because of traveler refusal, 966 (28%) because of provider decision, and 822 (24%) because of health systems barriers.
Beginning in 2012, providers assessed the reasons why travelers refused MMR vaccine (Figure) . Of the 958 travelers who refused MMR vaccine in 2012 or after, the most frequent reason cited for refusal was that the traveler was "not concerned about illness" (711 travelers [74%]). We also assessed the reasons why providers did not offer MMR vaccine to MMR-eligible travelers. Of the 966 travelers who were not vaccinated because of the provider's decision, most were not vaccinated (911 travelers [94%]) because the provider thought the MMR vaccine was not indicated; only 55 (6%) travelers were not vaccinated because the provider thought there was insufficient time before travel. Of the 822 travelers who were not vaccinated because of health systems barriers, the predominant barrier was referral to another provider for vaccination (812 travelers [99%]).
Most MMR-eligible travelers (51%) who were not vaccinated were evaluated at nonacademic sites ( Table  2) , even though only 27% of all travelers were seen at nonacademic sites ( Table 1) . Of the 1777 MMR-eligible travelers evaluated at nonacademic centers who were not vaccinated, 1178 (66%) were not vaccinated because of traveler refusal.
We further examined the differences observed in MMR eligibility and vaccination among GTEN sites in the U.S. census regions ( Table 3 ; demographic data are presented in Appendix Table 2 , available at Annals .org). Providers at the 8 clinical sites in the South eval- 
DISCUSSION
Routine assessment of measles immunity and vaccination with MMR before international travel is an essential means to reduce measles importations into the United States (20, 21) . We evaluated the clinical practice of MMR vaccination in GTEN, the largest consortium of clinical sites providing pretravel health care in the United States. Providers concluded that 16% of adults traveling internationally needed MMR vaccination at the time of their pretravel health consultation, yet more than half (53%) of those individuals were not vaccinated at the pretravel encounter. Our findings underscore the need for strategies to improve provider and traveler knowledge of measles as a travel-related illness and the need to increase pretravel uptake of the MMR vaccine. Improving vaccination rates is particularly important for communities with a higher percentage of nonimmune individuals because there is a greater risk for transmission events after an index case in these settings (10, 22, 23) .
Nonvaccination was most commonly due to traveler refusal of MMR, with lack of concern about measles cited as the most common reason. This is consistent with previous GTEN analyses of vaccine uptake at pretravel encounters (24) . Although clinics in the GTEN consortium are not selected on the basis of vaccination coverage in specific communities, traveler refusal was predominant in clinical sites in the South, suggesting geographic variability in the understanding of measles and the benefits of MMR vaccination (18) . Travelers were also more likely to refuse MMR vaccination after evaluation at nonacademic centers than at academic centers; patients evaluated in the South were not more likely to be seen at a nonacademic center. These findings support that providers may benefit from additional training on how to discuss beliefs regarding MMR vaccination and the realities of clinical illness with measles, which vaccine-hesitant patients often minimize (25, 26) . Few travelers in this study expressed concerns about MMR vaccine safety or cost; providers should ask travelers explicitly about any safety or cost concerns because travelers may not state them directly (27) .
Our findings also indicate that providers might benefit from education regarding pretravel MMR vaccination. More than one quarter of all missed opportunities for vaccination were because the provider did not recommend the MMR vaccine to eligible travelers. Providers at nonacademic centers, in particular, were less likely to recommend MMR vaccination to eligible travelers. This observation is consistent with previous work indicating that providers deviate from ACIP and CDC recommendations for other travel-related vaccines (28, 29) .
Health systems barriers played a role in 24% of missed opportunities for vaccination. In most instances, providers referred travelers to another provider, likely a primary care provider, for MMR vaccination. Although some travelers may have obtained MMR vaccination from a primary care provider before departure, attrition after referral may have occurred in some travelers because an additional clinic visit is required. Referral to another provider could be an attempt to ensure that (30) . Alternatively, providers could refer patients in an attempt to reduce costs for travelers because "travel-related" vaccinations are not uniformly covered by health insurance even if they are covered as part of routine care. Given the serious public health implications of undervaccination, strong consideration should be given to requiring insurers to cover MMR vaccination regardless of the site of delivery.
With more than 30 million U.S. residents traveling internationally by air every year (31), almost 5 million travelers could be at risk for measles when traveling abroad, if our study's findings apply to the overall population of U.S. travelers. MMR vaccination for nonimmune travelers could be a cost-effective strategy to reduce measles cases in the United States given the low cost of vaccination (32), the vaccine's 2-dose effectiveness of 97% (6) , and the low likelihood of vaccinerelated adverse events (33) , especially in the context of the morbidity and costs associated with measles infection (34 -36) , secondary cases caused by transmission (37, 38) , and the expensive outbreak investigations required with any new case of measles in the United States (37, 38) . Further evaluation of the costeffectiveness of pretravel measles vaccination is warranted given the low probability of exposure during travel but high impact of any imported measles cases.
Our study has limitations. Although GTEN is the largest consortium of clinics providing pretravel health consultations in the United States, clinical practice at GTEN sites may not be representative of all pretravel health consultations, and GTEN patients may not be representative of all U.S. travelers. In particular, healthseeking behavior may be more common among travelers who pursue a pretravel consultation; our study population may therefore be more likely to be up to date on routine vaccines and to agree to recommended vaccines than the general population of international travelers. Providers assessed measles immunity as it is commonly carried out in clinical practice, but their estimates may be imprecise. For instance, GTEN providers at times relied on immunization histories obtained by traveler recall and also allowed a history of measles illness and self-reported vaccination to be considered adequate evidence of measles immunity. This is more lenient than current ACIP guidelines (4, 5) , and measles immunity may therefore have been overestimated. However, an overestimation of measles immunity would result in even more opportunities for MMR pretravel vaccination than our analysis suggests. Because our study provides data only on actions taken at GTEN sites, we could not report the percentage of travelers who were successfully vaccinated with MMR by another provider before travel.
In conclusion, our results indicate that measles immunity could be increased among U.S. international travelers. Increasing measles immunity in travelers should substantially reduce the risk for measles importation and, by extension, decrease the number of new measles cases seen due to transmission within the United States. Strategies to improve traveler knowledge are essential to these efforts and should include materials specifically designed for travelers who express lack of concern about measles illness. Measles education strategies should also be targeted to providers and focus on geographic regions with low uptake of MMR vaccination for international travelers. Because MMR vaccination is recommended for all immunocompetent and non pregnant U.S. international travelers, primary care providers could play an important role in efforts to improve measles immunity in travelers. For instance, primary care providers could routinely ask patients about upcoming travel plans and vaccinate those eligible for MMR. Further study of the role of primary care providers in improving measles population immunity is warranted. In light of recent measles outbreaks associated with travel, pretravel measles immunity screening for U.S. adults traveling internationally and MMR vaccination for those eligible should be prioritized.
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